Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6)

Annel Lameijer,1 Marion J Fokkert,2 Mireille A Edens,3 Reinold O B Gans,4 Henk J G Bilo,5 Peter R van Dijk1

ABSTRACT

Introduction The FreeStyle Libre (FSL) is a flash glucose monitoring (FGM) system. The Flash Monitor Register in the Netherlands (FLARE-NL-4) study previously demonstrated the positive effects of FSL-FGM use during 1 year on glycemic control, quality of life and disease burden among persons with diabetes mellitus (DM). The present follow-up study assesses the effects of FSL-FGM after 2 years.

Research design and methods Patients included in the FLARE-NL-4 study who continued FSL-FGM during the 1-year study period were invited to participate (n=687). Data were collected using questionnaires (the 12-Item Short Form Health Survey version 2 (SF-122) and the EuroQol 5-Dimension 3-Level (EQ-5D-3L) for quality of life), including self-reported hemoglobin A1c (HbA1c).

Results A total of 342 patients agreed to participate: mean age 48.0 (±15.6) years, 52% men and 79.5% with type 1 DM. HbA1c decreased from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) mmol/mol after 2 years. At the end of the 2-year follow-up period, 260 (76%) persons were still using the FSL-FGM and 82 (24%) had stopped. The main reason for stopping FSL-FGM was financial constraints (55%). Concerning the whole 2-year period, there was a significant decrease in HbA1c among persons who continued use of FSL-FGM (−3.5 mmol/mol, 95% CI −6.4 to −0.7), while HbA1c was unaltered compared with baseline among persons who stopped FSL-FGM (−2.4 mmol/mol, 95% CI −7.5 to 2.7): difference between groups 2.2 (95% CI −1.3 to 5.8) mmol/mol. After 2 years, persons who continued use of FSL-FGM had higher SF-12 mental component score and higher EQ-5D Dutch tariff score and felt less often anxious or depressed compared with persons who discontinued FSL-FGM.

Conclusions Although the considerable number of non-responders limits generalizability, this study suggests that persons who continue to use FSL-FGM for 2 years may experience sustained improvement in glycemic control and quality of life.

INTRODUCTION

During the last decades real-time continuous glucose measurement (rt-CGM) has been introduced to measure glucose concentrations in the interstitial fluid. Flash glucose monitoring is a variant of rt-CGM in which the user obtains results intermittently by using a reader. In 2014, Freestyle Libre flash glucose monitoring (FSL-FGM, Abbott) was introduced. In contrast to most CGM devices, the FSL-FGM is already factory-calibrated with no need for daily calibration. Compared with fingerprick testing, FSL-FGM readings can be performed painless after insertion and provide additional information on trends in glucose levels during day and night.

In order to acquire evidence on the effects, efficacy and safety of use of FSL-FGM in the Netherlands, a nationwide registry (‘FLAsh monitor REgistry - NetherLands FLARE-NL’) was established in 2016.1 The FLARE-NL-4 study demonstrated a decrease
in hemoglobin A1c (HbA1c) (from 64 to 60 mmol/mol) over a 1-year study period and, importantly, improved the quality of life, decreasing rates of work absenteeism and fewer diabetes-related hospital admissions. These results were confirmed by other studies that also demonstrated improved glycemic control and quality of life. However, most of these studies are hampered by a limited study period (often <1 year).

In order to provide insight into the long-term use of FSL-FGM, the results of 2-year follow-up measurements among persons who participated in the FLARE-NL-4 study are described in the current study. Next to glycemic control, outcomes concerning quality of life and disease burden are presented.

**METHODS**

**Study design, patient selection and aims**

The FLARE-NL-4 register study had a prospective, observational design. Detailed information concerning the FLARE-NL registry and the 1-year outcomes have been published earlier. The present study aims to describe the effects of FSL-FGM at 2-year follow-up. We invited patients who participated in the 1-year FLARE-NL-4 study (n=1365) who had continued to use FSL-FGM for a minimum of 1 year (n=687). Invitations to participants were sent by email. A total of 342 patients agreed to participate in this 2-year follow-up study.

**Outcomes**

The primary outcome was glycemic control over the 2-year study period. Furthermore, changes in health-related quality of life and disease burden were investigated and comparisons were made between persons who continued use of FSL-FGM for at least 2 years and persons who stopped FSL-FGM before the 2-year follow-up was completed. Additionally, data were analyzed for persons with type 1 and type 2 diabetes mellitus (DM) separately.

**Study procedures**

After informed consent was obtained, study participants received a link to report their most recent HbA1c values and to fill out the online questionnaires regarding glycemic control, quality of life and disease burden. Glycemic control was assessed using self-reported most recent HbA1c values and the number of self-reported clinically significant hypoglycemias (defined as a glucose <3 mmol/L) in the past 6 months, measured with FSL-FGM or finger-prick testing. Additionally, participants were asked if they had experienced any hypoglycemic event during the past 6 months. Quality of life in the previous year was assessed by the EuroQol 5-Dimension 3-Level (EQ-5D-3L) questionnaire and the 12-Item Short Form Health Survey version 2 (SF-12v2). The EQ-5D is a generic measure developed by researchers from five European countries, including the Netherlands. The EQ-5D-3L is one of the most widely used instruments for measuring health-related quality of life. This questionnaire consists of two parts. The first is a descriptive system which comprises the following five dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension has three levels: no problems, some problems and extreme problems. The second is the EQ-5D Visual Analogue Scale from which a single overall score for self-rated health status can be elicited, ranging from 0 to 100. The EQ-5D Dutch tariff is a valuation of all possible EQ-5D-3L health states, based on estimated regression coefficients. This score ranges from 0 to 1, where 1 refers to full health and 0 refers to death. The SF-12 questionnaire measures eight health dimensions, among others general health, limitations in physical activities due to health problems, social functioning and vitality (energy/fatigue). The Physical Component Summary (PCS) and the Mental Component Summary (MCS) are two subscales derived from the SF-12. To investigate disease burden, the number of hospitalizations related to DM in the previous year and work absenteeism rate in the previous 6 months were measured using the questionnaire. In the FLARE-NL-4 study we strived for a more value-based healthcare approach. As such, the study also focused on patient-reported outcome measures (PROMs), using a list compiled in collaboration with the Dutch Diabetes Patient Association (Diabetes Vereniging Nederland; DVN) to assess the degree of disease burden experienced by the study population in relation to their DM and the usefulness of FSL-FGM. This questionnaire has been described in more detail previously and the questions as asked in the DVN-PROM can be found in the supplemental material attached to the FLARE-NL-4 paper.

**Statistical analyses**

Categorical data were expressed as n (%). To determine if variables were normally distributed, Q-Q plots and histograms were used. Normally distributed data were expressed as mean±SD and skewed distributed data as median with IQR. The Fisher’s exact test was used to analyze categorical variables. The Mann-Whitney U test was used to compare continuous variables if the data were distributed skewed. Linear mixed models with Bonferroni corrections were used to calculate estimated values (with 95% CI) and to test for differences between the three moments in time (t=0, t=1 and t=2 years) and between groups. In the model the fixed factors continued and stopped FSL-FGM were used as determinants. The difference in scores was determined based on the b-coefficient of each particular (continued or stopped FSL-FGM use) group. Significance of the b-coefficient was investigated with the Wald test based on p<0.05. The quantity of the b-coefficient, with 95% CI, gives the
difference between both treatment modalities over the study period adjusted for baseline differences. Statistical analyses were performed using SPSS V.26.0. A significance level of 5% (two-sided) was used.

RESULTS

A total of 342 persons of the invited 687 (49.8%) agreed to participate in this follow-up study. As presented in table 1, 178 (52.0%) of the participants were men, with a mean age of 48.0 (±15.6) years and the majority of the population (79.5%) with type 1 DM.

Changes over time among all participants are presented in table 2. HbA1c decreased significantly from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) after 2 years.

Concerning quality of life, the SF-12 PCS increased over time among all participants. HbA1c decreased significantly from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) after 2 years.

The SF-12 MCS remained stable among persons who continued FSL-FGM use over the 2-year period. Over the whole study period, the difference in SF-12 MCS change, as well as the difference in change of the EQ-5D Dutch tariff score, was significantly better among persons who continued FSL-FGM use as compared with persons who stopped (difference: 5.0 (95% CI 2.7 to 7.3) and 0.07 (95% CI 0.02 to 0.1), respectively). The SF-12 PCS increased in both groups. After 2 years, the percentage of persons who reported work absenteeism and hospital admission was lower for persons who continued FSL-FGM as compared with persons who stopped FSL-FGM (5.0% vs 14.6% (p<0.01) and 5.4% vs 12.2% (p<0.05), respectively, presented in online supplemental table 4).

Online supplemental table 2 and 3 show the effects of use of FSL-FGM on changes in glycemic control, quality of life and disease burden for persons with type 1 DM (n=272) and type 2 DM (n=45) separately. The significant changes described above concerning HbA1c, SF-12 PCS, SF-12 MCS and EQ-5D Dutch tariff score among persons who continued FSL-FGM were also observed among persons with type 1 DM who continued FSL-FGM.

As presented in online supplemental table 5, when comparing the outcomes of the DVN-PROM questionnaire after 2 years of follow-up between persons who continued and persons who stopped FSL-FGM, persons who continued FSL-FGM reported their hypoglycemic episodes were less severe (81.9% vs 11.4%), performed more adjustments of insulin dose (81.9% vs 30.4%), had a better understanding of glucose fluctuations (94.5% vs 7.6%), more often measured their glucose levels prior to traffic participation (65.4% vs 39.2%) and participated more frequently in sports activities (42.9% vs 3.8%). Importantly, persons who used the FSL-CGM felt more secure (77.2% vs 8.9%). Furthermore, people with whom they live together were less concerned about the glucose regulation of their partner (65.0% vs 9.0%).
DISCUSSION

In the present study we describe follow-up data concerning FSL-FGM derived from a nationwide registry. HbA1c decreased significantly after 2 years of follow-up. Among persons who continued FSL-FGM during the whole 2-year period, there was HbA1c reduction of −3.5 mmol/mol (95% CI −6.4 to −0.7), while HbA1c remained unchanged among persons who stopped FSL-FGM. Importantly, we observed significant (sustained) improvements in readouts of quality of life (SF-12 MCS, EQ-5D Dutch tariff score, and levels of anxiety and depression) among persons who continued FSL-FGM compared with persons who stopped.

The observed association between HbA1c improvement and FSL-FGM use is in line with recent publications. The current study adds by demonstrating a significant HbA1c improvement over a 2-year period among FSL-FGM users. We were unable to demonstrate a difference in change of HbA1c over the 2-year study period between persons who continued FSL-FGM and those who stopped before the 2-year follow-up was completed. We hypothesize that this is related to the fact that the group of persons who stopped FSL-FGM had already used FSL-FGM for at least 1 year, which likely has provided them with more insight into their glucose regulation (and fluctuations). We expect this ‘learning effect’ to have a positive influence on glycemic control during the following months after discontinuation of FSL-FGM.

The number of reported hypoglycemic events after 2 years of FSL-FGM use was not different as compared with baseline. However, the percentage of persons who detected at least one episode of hypoglycemia was higher among FSL-FGM users compared with persons who stopped. Importantly, in the DVN-PROM questionnaire, FSL-FGM users reported their hypoglycemic episodes to be less severe. Charleer et al found a higher number of perceived hypoglycemic episodes among FSL-FGM users as compared with the period when they used self-monitoring of blood glucose (SMBG), possibly related to more detailed insight into glucose fluctuations.

Table 2 Changes in glycemic control, quality of life and disease burden among all participants

| Table 2 | Changes in glycemic control, quality of life and disease burden among all participants |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Baseline (A) | 1 year (B) | 2 years (C) | B vs A | C vs A | C vs B |
| Glycemia | | | | | |
| HbA1c | 60.7 (59.1 to 62.3) | 57.3 (55.8 to 58.8) | 57.8 (56.0 to 59.5) | −3.4 (−6.1 to −0.7) | −2.9 (−5.9 to −0.02) | 0.5 (−2.4 to 3.3) |
| n | 341 | 253 | 342 | | | |
| Hypoglycemic events in the past 6 months | 64.7 (55.3 to 74.0) | 66.3 (55.0 to 77.6) | 51.0 (42.1 to 59.9) | 1.6 (−16.2 to 19.5) | −13.6 (−29.4 to 2.1) | −15.3 (−32.8 to 2.3) |
| n | 325 | 311 | 294 | | | |
| Quality of life | | | | | |
| EQ-5D-3L Dutch tariff | 0.8 (0.8 to 0.9) | 0.9 (0.8 to 0.9) | 0.8 (0.8 to 0.9) | 0.01 (−0.03 to 0.05) | 0.0 (−0.04 to 0.04) | −0.01 (−0.05 to 0.03) |
| n | 342 | 342 | 336 | | | |
| EQ-VAS | 69.8 (67.4 to 72.2) | 71.7 (69.0 to 74.4) | 73.9 (71.0 to 76.9) | 1.9 (−2.5 to 6.3) | 4.1 (−0.5 to 8.7) | 2.2 (−2.6 to 7.1) |
| n | 342 | 342 | 336 | | | |
| SF-12PCS score | 38.2 (37.4 to 38.9) | 47.2 (46.2 to 48.2) | 46.9 (45.9 to 47.9) | 9.1 (7.6 to 10.6) | 8.7 (7.2 to 10.2) | −0.4 (−2.1 to 1.4) |
| n | 342 | 342 | 342 | | | |
| SF-12MCS score | 48.8 (47.6 to 50.1) | 49.4 (48.3 to 50.5) | 47.5 (46.4 to 48.7) | 0.6 (−1.5 to 2.6) | −1.3 (−3.4 to 0.8) | −1.9 (−3.8 to 0.03) |
| n | 342 | 333 | 333 | | | |
| Disease burden | | | | | |
| Hospital admissions | 0.1 (0.04 to 0.2) | 0.1 (−0.01 to 0.1) | 1.3 (−2.2 to 4.8) | −0.1 (−0.2 to 0.1) | 1.2 (−3.1 to 5.5) | 1.3 (−3.0 to 5.6) |
| n | 342 | 342 | 341 | | | |
| Lost working days | 6.0 (2.7 to 9.3) | 5.1 (2.2 to 8.0) | 5.7 (1.5 to 9.9) | −0.9 (−6.3 to 4.5) | −0.3 (−6.8 to 5.6) | 0.6 (−5.6 to 6.8) |
| n | 342 | 342 | 339 | | | |

Data are presented as mean (difference) with 95% CI. HbA1c concentrations are presented in mmol/mol. EQ-5D-3L, three-level version of EuroQol 5 Dimension; EQ-VAS, EQ-Visual Analogue Scale; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12, 12-item Short Form Health Survey version 2.

Table 3 Reasons for discontinuing FSL-FGM

| Table 3 | Reasons for discontinuing FSL-FGM |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Reason for stopping FSL-FGM | n (%) | | | |
| Financial constraints | 45 (54.9) | | | |
| End of the study | 11 (13.4) | | | |
| Unsatisfied with ease of use | 3 (3.7) | | | |
| Allergy to the adhesives | 3 (3.7) | | | |
| Use of an alternative to FSL-FGM | 3 (3.7) | | | |
| Inadequate glucose regulation despite FSL-FGM | 1 (1.2) | | | |
| FSL-FSG is regarded unreliable | 1 (1.2) | | | |
| Undefined | 15 (18.3) | | | |
| Total | 82 (100) | | | |
Table 4  Changes in glycemic control, quality of life and disease burden among persons who continued FSL-FGM for at least 2 years and persons who had stopped FSL-FGM before the 2-year follow-up period was completed

|                          | Baseline (A) | 1 year (B) | 2 years (C) | C vs A | C vs B | Overall difference between groups |
|--------------------------|-------------|------------|-------------|-------|-------|----------------------------------|
|                          | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM | Continued FSL-FGM | Stopped FSL-FGM |
| **Glycemia**             |             |            |             |       |       |                                  |
| HbA1c                    | 62.4 (60.8 to 64.0) | 59.0 (56.2 to 61.8) | 58.3 (56.8 to 59.7) | 56.4 (53.8 to 59.9) | 56.7 (53.6 to 59.8) | 3.5 (−6.4 to −0.7) | −2.4 (−7.5 to 2.7) | 0.6 (−2.1 to 3.4) | 0.3 (−4.6 to 5.2) | 2.2 (−1.3 to 5.8) |
| n                        | 259         | 82         | 260         | 82    |       |                                  |
| Hypoglycemic events      | 61.8 (52.8 to 70.8) | 67.5 (51.1 to 83.9) | 60.3 (49.7 to 70.9) | 72.3 (52.4 to 92.2) | 51.3 (43.0 to 59.7) | −10.5 (−25.4 to 4.5) | −16.8 (−44.5 to 10.9) | −9.0 (−25.5 to 7.5) | −21.6 (−52.5 to 9.4) | 0.6 (−17.2 to 18.4) |
| n                        | 250         | 75         | 242         | 69    | 229   | 65                                |
| **Quality of life**       |             |            |             |       |       |                                  |
| EQ-VAS                   | 70.9 (69.5 to 74.2) | 67.7 (63.6 to 71.9) | 73.8 (71.2 to 76.4) | 69.6 (64.9 to 74.2) | 74.8 (71.9 to 77.6) | 2.9 (−1.7 to 7.4) | 5.3 (−2.8 to 13.4) | 0.9 (−3.8 to 5.7) | 3.5 (−5.0 to 12.0) | 1.7 (−4.2 to 7.6) |
| n                        | 260         | 82         | 260         | 82    | 265   | 80                                |
| EQ-5D-3L Dutch tariff     | 0.85 (0.83 to 0.87) | 0.84 (0.80 to 0.88) | 0.87 (0.85 to 0.90) | 0.84 (0.80 to 0.88) | 0.88 (0.85 to 0.89) | 0.81 (0.77 to 0.89) | −0.02 (−0.02 to 0.06) | −0.03 (−0.10 to 0.04) | −0.02 (−0.04 to 0.04) | −0.03 (−0.1 to 0.04) | 0.07 (0.02 to 0.1) |
| n                        | 260         | 82         | 260         | 82    | 256   | 80                                |
| SF-12v2 PCS score        | 37.6 (36.9 to 38.3) | 38.7 (37.5 to 40.0) | 47.4 (46.4 to 48.4) | 47.1 (45.3 to 48.8) | 47.2 (46.2 to 48.2) | 46.5 (44.8 to 48.3) | 9.6 (8.1 to 11.0) | 7.8 (5.2 to 11.5) | −0.2 (−1.9 to 1.5) | −0.5 (−3.5 to 2.5) | 0.7 (−1.4 to 2.7) |
| n                        | 260         | 82         | 260         | 82    | 260   | 82                                |
| SF-12v2 MCS score        | 50.1 (48.8 to 51.3) | 47.6 (45.4 to 49.9) | 51.1 (50.0 to 52.1) | 47.8 (45.9 to 49.6) | 50.0 (48.9 to 47.0) | −0.03 (−2.1 to 2.0) | −2.6 (−6.2 to 1.1) | −1.1 (−2.9 to 0.8) | −2.7 (−6.1 to 0.6) | 5.0 (2.7 to 7.3) |
| n                        | 260         | 82         | 260         | 82    | 254   | 79                                |
| **Disease burden**       |             |            |             |       |       |                                  |
| Hospital admissions      | 0.1 (0.07 to 0.2) | 0.1 (−0.04 to 0.2) | 0.1 (0.03 to 0.2) | 0.02 (−1.0 to 0.1) | 2.1 (−1.4 to 5.5) | 0.6 (−5.5 to 6.7) | 1.9 (−2.3 to 6.1) | 0.5 (−7.0 to 8.0) | 2.0 (−2.2 to 6.2) | 0.6 (−6.9 to 8.1) | 2.1 (−1.4 to 5.5) |
| n                        | 260         | 82         | 260         | 82    | 259   | 82                                |
| Lost working days        | 4.9 (1.6 to 8.1) | 7.2 (1.4 to 13.0) | 2.2 (−0.7 to 5.0) | 8.0 (3.0 to 13.1) | 3.4 (−0.7 to 7.5) | 8.0 (3.0 to 13.1) | −1.5 (−7.9 to 4.9) | 0.9 (−10.5 to 12.2) | 1.2 (−4.9 to 7.3) | 0.01 (−10.8 to 10.8) | −4.6 (−13.0 to 3.7) |
| n                        | 260         | 82         | 260         | 82    | 257   | 82                                |

Data are presented as mean (difference) with 95% CI. HbA1c concentrations are presented in mmol/mol. EQ-SD-3L, three-level version of EuroQol 5-Dimension; EQ-VAS, EQ-Visual Analogue Scale; FSL-FGM, FreeStyle Libre flash glucose monitoring; HbA1c, hemoglobin A1c; MCS, Mental Component Summary; PCS, Physical Component Summary; SF-12v2, 12-Item Short Form Health Survey version 2.
with FSL-FGM and a reduction of self-reported severe hypoglycemia.

Overall, continuing FSL-FGM was associated with improved quality of life, as compared with patients stopping FSL-FGM. Other studies have highlighted the positive influence of FSL-FGM on quality of life among persons with DM. Overend et al. reported a positive impact of FSL-FGM on psychological well-being and self-esteem as patients with type 1DM experienced more control over their blood glucose values. The authors attributed a reduction in frequency, severity and fear of hypoglycemia as the key positive impact on well-being. In line with these observations, the current study showed an improvement in understanding of glucose fluctuations among FSL-FGM users, and possibly related to this enhancement they felt more secure. The positive impact of FSL-FGM on quality of life is also supported by the results of the EQ-5D-3L questionnaire: among patients who continued use of FSL-FGM for 2 years, the reported level of anxiety and depression was significantly lower compared with patients who stopped FSL-FGM (online supplemental table 3).

In the FLARE-NL-4 study a decrease in work absenteeism rate (within 6 months) and in annual diabetes-related hospital admission rate was observed. Previous studies also showed a decrease in diabetes-related work absenteeism and hospital admissions after initiation of FSL-FGM. The current follow-up study showed that stopping FSL-FGM was associated with a deterioration in the percentage of persons who reported work absenteeism and diabetes-related hospital admissions, compared with persons who continued FSL-FGM.

Of note, during the 1-year FLARE-NL-4 study, patients had to finance half of the cost of the FSL-FGM themselves if they did not fulfill the Dutch criteria for FSL-FGM reimbursement, and during the second year of use this group (56% of persons) had to pay the full amount (approximately €120 per month) themselves. This study demonstrated that 24% of persons stopped FSL-FGM use after the first year. For these persons financial constraints were the main reason for stopping.

This study has several limitations. Data were obtained from a nationwide registry and follow-up questionnaires and as such lacked a comparator. As discussed, a considerable number of persons included in the original FLARE-NL-4 study did not participate in the present follow-up study, potentially resulting in selection bias. Importantly, in this study we did not have access to FSL-FGM data; therefore, information concerning glucose metrics such as time in range is not available. Furthermore, information about the frequency of glucose monitoring, known to be associated with better glycemic control, was not included in the database. As data were patient-reported, recall bias may be present. The exact time point when participants stopped using FSL-FGM is unknown.

Since the majority of participants had to finance the costs of the FSL-FGM themselves after 1 year, this inevitably will contribute to selection bias, since the actual participants probably will be more affluent than the average DM population, which may be related to a higher quality of life among FSL-FGM users. Patients used FSL-FGM for several indications, as described in the FLARE-NL-4 study.

Finally, it should be mentioned that one of the questionnaires (the ‘DVN-PROM’) used in this study has not been validated yet. Although the DVN-PROM was non-validated, we still find the results valuable and useful as they represent the results of a collaboration with a DM patient organization and FSL-FGM users and the questions asked are very recognizable for both caregivers and patients.

CONCLUSION

Although a considerable number of persons from the original FLARE-NL-4 study were unavailable for this follow-up study, the data suggest that FSL-FGM use by persons with DM for a 2-year period was associated with sustained improvement of self-reported HbA1c compared with the period before FSL-FGM use. Aspects of experienced quality of life were higher among persons who continued FSL-FGM as compared with persons who discontinued FSL-FGM before the 2-year follow-up period was completed. Financial motives were the main reason for discontinuing FSL-FGM.

Acknowledgements We thank all the participants for allowing us to use their data for the study and Jeanette Braakman for data collection.

Contributors AL: statistical analysis, interpretation of data, writing of the manuscript. MJF: collection of data, critical review of the manuscript. MAE: interpretation of data, critical review of the manuscript. ROBG: critical review of the manuscript. HJGB: design, critical review of the manuscript. PRVD: design, statistical analysis, interpretation of data, critical review of the manuscript. All authors approved the final version of the manuscript.

Funding The FLARE-NL registry was funded by an unconditional grant (number Z699) from Stichting Achmea Gezondheidszorg (SAG). The SAG is an innovation fund of the health insurance company ZilverenKruis. The manufacturer of the FreeStyle Libre (Abbott) did not provide any finances for the proposed study and did not have any influence on study design nor on the definition of the target groups or the study objectives.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the Medical Ethical Committee of Isala (Zwolle, The Netherlands) (METC 16.0346).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available via the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,
BMJ Open Diabetes Res Care 2021;9:e002124. doi:10.1136/bmjdrc-2021-002124

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**
Annel Lameijer http://orcid.org/0000-0003-2407-3370
Marion J Fokkert http://orcid.org/0000-0002-4687-1157
Mireille A Edens http://orcid.org/0000-0001-5449-5035
Peter R van Dijk http://orcid.org/0000-0002-9702-6551

**REFERENCES**

1. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care 2019;7:e000809.

2. Castellana M, Parisi C, Di Molfetta S, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Res Care 2020;8:e001092.

3. Mancini G, Berioli MG, Santi E, et al. Flash glucose monitoring: a review of the literature with a special focus on type 1 diabetes. Nutrients 2018;10. doi:10.3390/nu10080992. [Epub ahead of print: 29 Jul 2018].

4. Rouhard S, Buysschaert M, Alexopoulou O, et al. Impact of flash glucose monitoring on glycaemic control and quality of life in patients with type 1 diabetes: a 18-month follow-up in real life. Diabetes Metab Syndr 2020;14:65–9.

5. Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of British clinical diabetologists (ABCD) nationwide audit. Diabetes Care 2020;43:dc200738.

6. Ang E, Lee ZX, Moore S, et al. Flash glucose monitoring (FGM): a clinical review on glycaemic outcomes and impact on quality of life. J Diabetes Complications 2020;34:107559.

7. Fokkert MJ, Damman A, van Dijk PR, et al. Use of freestyle libre flash monitor register in the Netherlands (FLARE-NL1): patient experiences, satisfaction, and cost analysis. Int J Endocrinol 2019;2019:1–6.

8. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American diabetes association and the European association for the study of diabetes, Diabetes Care 2017;40:155–7.

9. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

10. Van Reenen M, Janssen B. EQ-5D-3L user guide: basic information on how to use the EQ-5D-3L instrument. Rotterdam, Netherlands: EuroQol Research Foundation, 2015.

11. Lammers LM, Stalmieper PFM, McDonnell J. “Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief,”. Nederlands Tijdschrift Voor Geneeskunde 2005;149:1574–7 https://www.ntvg.nl/artikelen/kwaliteit-van-leven-meten-economische-evaluaties-het-nederlands-eq-5d-tarief/artikelinfo

12. Lamers LM, Stalmieper PFM, McDonnell J, et al. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd 2005;149:1574–8.

13. Ware J, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.

14. Evans M, Welsh Z, Ellis S, et al. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther 2020;11:83–95.

15. Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently Scanned continuous glucose monitoring in adults living with type 1 diabetes (future): a prospective observational real-world cohort study. Diabetes Care 2020;43:389–97.

16. Tyndall V, Stimson RH, Zammitt NN, et al. Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 2019;62:1349–56.

17. Overend L, Simpson E, Grimwood T. Qualitative analysis of patient responses to the ABCD freestyle libre audit questionnaire. Pract Diab 2019;36:45–50.

18. Kramer G, Michalak L, Müller UA, et al. Association between flash glucose monitoring and metabolic control as well as treatment satisfaction in outpatients with diabetes type 1. Exp Clin Endocrinol Diabetes 2021;129:303–8.

19. Al Hayek AA, Al Dawish MA. The potential impact of the freestyle libre flash glucose monitoring system on mental well-being and treatment satisfaction in patients with type 1 diabetes: a prospective study. Diabetes Ther 2019;10:1539–48.

20. Lameijer A, Lommerde N, Dunn TC, et al. Flash glucose monitoring in the Netherlands: increased monitoring frequency is associated with improvement of glycemic frequency. Diabetes Res Clin Pract 2021;177:108897.